Comparative Pharmacology
Head-to-head clinical analysis: MACRODANTIN versus UROBAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACRODANTIN versus UROBAK.
MACRODANTIN vs UROBAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial acetyl-CoA carboxylase, interfere with bacterial cell wall synthesis, and damage bacterial DNA. It is bactericidal against a broad spectrum of gram-positive and gram-negative bacteria.
UROBAK (methenamine hippurate) is a prodrug that hydrolyzes to formaldehyde in acidic urine (pH ≤ 5.5). Formaldehyde denatures bacterial proteins and nucleic acids, exerting a broad-spectrum bacteriostatic effect. The hippurate component may enhance urinary acidification.
100 mg orally twice daily for 5 days; for uncomplicated UTI. Route: oral. Frequency: twice daily.
500 mg orally once daily
None Documented
None Documented
20-60 minutes (prolonged in renal impairment, up to 8 hours in anuria)
6-8 hours (prolonged in renal impairment).
Renal: 30-40% unchanged, Hepatic metabolism: 60-70% to inactive metabolites, Fecal: <1%
Primarily renal (85% unchanged); 15% biliary/fecal.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective